Guided Therapeutics (GTHP) EBITDA Margin (2010 - 2025)
Guided Therapeutics' (GTHP) quarterly EBITDA Margin came in at 120.34% in Q4 2025, up 5327966.0% year-over-year from N/an in Q4 2024, and up 85.11% quarter-over-quarter from 808.33% in Q3 2025.
Powered by 
Analysis
Guided Therapeutics (GTHP) EBITDA Margin (2010 - 2025) Analysis & Trends
Guided Therapeutics has disclosed EBITDA Margin across 16 years of filings, most recently posting 120.34% for Q4 2025.
- In Q4 2025, EBITDA Margin rose 5327966.0% year-over-year to 120.34%; the TTM figure through Jun 2026 stood at 303.85% (up 162158.0% YoY), while the FY2025 annual figure was 309.26%, up 2980503.0% from the prior year.
- EBITDA Margin came in at 120.34% for Q4 2025 at Guided Therapeutics, up from 808.33% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 120.34% in Q4 2025 to a low of 53400.0% in Q4 2024.
- Average EBITDA Margin over 5 years is 11790.73%, with a median of 3626.14% recorded in 2023.
- Year-over-year, EBITDA Margin sank 5188438 bps in 2024 and soared 5327966 bps in 2025.
- Over 5 years, EBITDA Margin stood at 725.0% in 2021, then tumbled by 5528 bps to 40800.0% in 2022, then soared by 96 bps to 1515.62% in 2023, then plunged by 3423 bps to 53400.0% in 2024, then jumped by 100 bps to 120.34% in 2025.
- Per Business Quant data, the three most recent EBITDA Margin figures were 120.34% in Q4 2025, 808.33% in Q3 2025, and 652.14% in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.04 Bn | 177.44 Bn | 7.27 Bn | 13.44% |
| 2 | Intuitive Surgical | 125.02 Bn | 119.81 Bn | 1.96 Bn | 33.60% |
| 3 | Medtronic | 117.84 Bn | 109.02 Bn | 6.34 Bn | 18.08% |
| 4 | Stryker | 105.50 Bn | 102.02 Bn | 4.50 Bn | 25.18% |
| 5 | Boston Scientific | 66.27 Bn | 65.73 Bn | 3.85 Bn | 21.65% |
| 6 | Edwards Lifesciences | 49.60 Bn | 45.35 Bn | 1.35 Bn | 29.48% |
| 7 | Alcon | 33.70 Bn | 32.24 Bn | 1.68 Bn | 0.40% |
| 8 | Dexcom | 32.06 Bn | 30.11 Bn | 830.00 Mn | 24.33% |
| 9 | Steris | 21.02 Bn | 20.54 Bn | 684.20 Mn | 19.15% |
| 10 | Guided Therapeutics | 24.13 Mn | 24.12 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -120.34% |
| Sep 30, 2025 | -808.33% |
| Jun 30, 2025 | -652.14% |
| Dec 31, 2024 | -53,400.00% |
| Mar 31, 2024 | -5,983.33% |
| Dec 31, 2023 | -1,515.63% |
| Jun 30, 2023 | -3,420.45% |
| Mar 31, 2023 | -3,831.82% |
| Sep 30, 2022 | -40,800.00% |
| Jun 30, 2022 | -14,340.00% |
| Mar 31, 2022 | -8,860.00% |
| Dec 31, 2021 | -725.00% |
| Sep 30, 2021 | -2,563.16% |
| Jun 30, 2021 | -28,050.00% |
| Dec 31, 2020 | -1,152.00% |
| Sep 30, 2020 | -198.70% |
| Dec 31, 2019 | -1,031.25% |
| Sep 30, 2019 | -18,800.00% |
| Jun 30, 2019 | -32,700.00% |
| Mar 31, 2019 | -1,427.78% |